Asset profile
Risperidone (Risperdal)
Small molecule
Evidence outlook
Approved: Schizophrenia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 27 direct rivals (same mechanism and indication), 0 same-class, 40 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Risperidone (Risperdal): this drug | Approved | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Clozapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Fazaclo | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Iloperidone (PD Psychosis Use) (Fanapt) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Loxapine (Adasuve) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Lumateperone (Caplyta) | Approved | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | ||
| Lurasidone | Approved | Small molecule | Dopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Milsaperidone (VHX-896) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Olanzapine (Zyprexa Relprevv) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Olanzapine (Zyprexa) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone (Invega) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone Palmitate (Erzofri) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone Palmitate (Invega Hafyera) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone Palmitate (Invega Sustenna) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone Palmitate (Invega Trinza) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) |
…and 52 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
21 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(13 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
2027 (7)
April 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (1)
What to watch
September 2027 (1)
What to watch
December 2027 (3)
What to watch
What to watch
2028 (2)
2029 (1)
December 2029 (1)
What to watch
2030 (1)
July 2030 (1)
What to watch
2032 (1)
February 2032 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.